123731-35-1

Upstream product

• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 

Downstream Products

• 139462-22-9 <4S>-3-<2--N-Methylamino>-1-oxoethyl>-4-(phenylmethyl)-2-oxazolidinone 
• 90719-50-9 (4S)-3-((E,E)-2',7',9'-decatrienoyl)-4-(phenylmethyl)-2-oxazolidinone 
• 135396-76-8 (4S)-3-<(E)-4-methyl-1-oxohept-4-enyl>-4-(phenylmethyl)oxazolidin-2-one 
• 138323-01-0 (R)-4-benzyl-3-(5,5-dimethoxypentanoyl)-2-oxazolidinone 
• 128677-88-3 (4S)-N-[(3R)-phenylbutanoyl]-4-phenylmethyl-1,3-oxazolidin-2-one 
• 128693-82-3 (3(3R),4S)-4-benzyl-3-<3-(4'-methoxyphenyl)butanoyl>-2-oxazolidinone 
• 145022-59-9 (S)-4-benzyl-3-(5,5-ethylenedioxypentanoyl)-2-oxazolidinone 
• 101711-89-1 (S)-4-Benzyl-3-[4-(4-methoxy-benzyloxy)-butyryl]-oxazolidin-2-one 
• 155697-48-6 (S)-4-Benzyl-3-[(S)-3-(3-benzyloxy-phenyl)-4,4-difluoro-butyryl]-oxazolidin-2-one 
• 155697-47-5 (S)-4-Benzyl-3-[(R)-3-(3-benzyloxy-phenyl)-4,4-difluoro-butyryl]-oxazolidin-2-one 
• 169897-87-4 [4S]-4-benzyl-3-(4-benzyloxy-1-butanoyl)-2-oxazolidinone 
• 111292-87-6 (S)-4-benzyl-3-butyryloxazolidin-2-one 
• 174192-14-4 (S)-4-Benzyl-3-[3-(dicyclohexyl-phosphinothioyl)-propionyl]-oxazolidin-2-one 
• 202344-78-3 (S)-4-phenylmethyl-3-(1'-oxononanoyl)-2-oxazolidinone 

Relevant academic research and scientific papers

3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS

The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.

Syntheses of all the stereoisomers of butanol type 1,7-seco-2,7′-cyclolignane

All the stereoisomers of butanol type 1,7-seco-2,7′-cyclolignane were stereoselectively synthesized by employing (S)- and (R)-Evans' auxiliaries to construct the stereochemistry. (+)- and (-)-Kadangustin J and their diastereomers were also prepared. The optical purity of the synthesized butanol type 1,7-seco-2,7′-cyclolignane was more than 99%ee.

Asymmetric synthesis of (E)-dehydroapratoxin A

An asymmetric approach to key intermediate 17 starting from lactone 7 is described, in which Evan's alkylation and CBS-catalyzed reduction are used for construction of the chiral centers, respectively. Thus, the synthesis of (E)-dehydroapratoxin A 6 could

N-FORMYL HYDROZYAMINE COMPOUNDS

Novel N-formyl hydroxylamine compounds and their derivatives are disclosed. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compou

N-FORMYL HYDROXYLAMINE COMPOUNDS

Novel N-formyl hydroxylamine compounds and their derivatives are disclosed. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compou

Melanocortin receptor ligands

Disclosed are MC-4 and/or MC-3 receptor ligands, the ligands having a structure according to Formula (I): wherein R2, R4, R4′, R5, R6, R6′, R7, R8, R8′, R9, R9′, R10, Ar, Z1, Z2, Z3, X, B, D, p, q, r and s are as described in the specification and claims, and optical isomers, diastereomers or enantiomers thereof; pharmaceutically-acceptable salts, hydrates, and biohydrolyzable esters, amides or imides thereof. Also disclosed are pharmaceutical compositions comprising the ligands of Formula (I), as well as methods of treating diseases mediate by the MC-4/MC-3 receptors, as described in the Detailed Descriptions section of the specification.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.

Compounds for treating tumors

The invention provides compounds of formula (I): wherein E, A, B′, R6, R7, R8, and R9 are defined in the specification which compounds exhibit anticancer activity and are useful for treating cancer.

GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, W, X, and n are defined herein, which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.